Back

Chronic Antigen Stimulation in Solid Tumors Induces T Cell Exhaustion and Limits Efficacy of T Cell Bispecific Therapies

Hutter-Karakoc, I.; Varypataki, E. M.; Neelakandhan, A.; Lang, S.; Kramar, V.; Varol, A.; Simons, S.; Richard, M.; Pincha, M.; Venetz, D.; Joller, N.; Muenz, C.; Umana, P.; Klein, C.; Amann, M.

2025-02-02 cancer biology
10.1101/2025.01.29.635556 bioRxiv
Show abstract

T cell bispecific antibodies (TCBs) have demonstrated promising results in patients with solid tumors. However, the underlying immunological and molecular mechanisms influencing these clinical outcomes require in depth evaluation. T cell exhaustion, a state induced by prolonged antigen exposure, is known to undermine T cell-based immunotherapies, though its specific impact on TCB efficacy remains unclear. In this study, we assessed the effectiveness of TCBs on tumor-specific T cells, focusing on their functional status. Utilizing a fully immunocompetent mouse model with a solid tumor expressing an immunogenic antigen, we showed that tumor-specific T cells acquire an exhausted phenotype and fail to expand under TCB treatment. By employing both mouse and human tumor-specific T cells in vitro, our study established that chronically stimulated tumor-specific T cells show impaired response to TCB treatment. The comparison of TCB efficacy in T cell-inflamed tumors with immunogenic antigens versus non-inflamed tumors with low antigen presence in mice revealed TCB success in solid tumors is more reliant on T cell functional fitness than on their abundance before treatment. The data also indicate that solid tumors with elevated levels of both, intratumoral regulatory T cells, and T cells expressing co-inhibitory receptors, show diminished responses to TCB therapy, aligning with similar observations described in hematological cancers. These findings highlight the critical role of T cell exhaustion due to chronic antigen exposure and illustrate that exhausted tumor-specific T cells are likely not the driver population redirected by TCBs for tumor elimination. Our research highlights the importance of maintaining T cell fitness and preventing T cell exhaustion to improve TCB therapy outcomes. This may help better identify patient populations with solid tumors that could benefit from TCB treatments most in clinical settings.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
OncoImmunology
22 papers in training set
Top 0.1%
14.1%
2
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.1%
14.1%
3
Cancers
200 papers in training set
Top 0.6%
8.3%
4
Cancer Immunology, Immunotherapy
11 papers in training set
Top 0.1%
4.8%
5
Blood Advances
54 papers in training set
Top 0.3%
4.3%
6
Frontiers in Oncology
95 papers in training set
Top 1.0%
3.9%
7
Cancer Immunology Research
34 papers in training set
Top 0.1%
3.5%
50% of probability mass above
8
eLife
5422 papers in training set
Top 30%
3.0%
9
Cancer Research Communications
46 papers in training set
Top 0.2%
3.0%
10
Antibody Therapeutics
16 papers in training set
Top 0.1%
2.6%
11
PLOS ONE
4510 papers in training set
Top 49%
2.0%
12
Scientific Reports
3102 papers in training set
Top 54%
1.9%
13
Blood
67 papers in training set
Top 0.8%
1.7%
14
Nature Communications
4913 papers in training set
Top 57%
1.2%
15
Molecular Oncology
50 papers in training set
Top 0.6%
1.2%
16
Cell Reports Medicine
140 papers in training set
Top 5%
1.2%
17
npj Precision Oncology
48 papers in training set
Top 0.9%
1.2%
18
Frontiers in Immunology
586 papers in training set
Top 6%
1.2%
19
Leukemia
39 papers in training set
Top 0.6%
1.1%
20
Blood Cancer Journal
11 papers in training set
Top 0.2%
0.9%
21
Cell Communication and Signaling
35 papers in training set
Top 0.8%
0.9%
22
Journal of Hematology & Oncology
10 papers in training set
Top 0.1%
0.9%
23
Molecular Cancer Therapeutics
33 papers in training set
Top 0.6%
0.9%
24
Clinical Cancer Research
58 papers in training set
Top 2%
0.8%
25
EBioMedicine
39 papers in training set
Top 1%
0.7%
26
Cancer Research
116 papers in training set
Top 3%
0.7%
27
Cell Reports
1338 papers in training set
Top 34%
0.7%
28
Science Advances
1098 papers in training set
Top 32%
0.7%
29
iScience
1063 papers in training set
Top 38%
0.6%
30
Cancer Cell
38 papers in training set
Top 2%
0.6%